Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 7:22 p.m. and Nov. 22, 2024, 7:22 p.m.
from: Fertility Technology.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 19, 2024, 8:30 a.m. / Source: PR Newswire
Activity Class: CorporateFinanceActivity
/ Type: Investment
Investor:
Target:
Document Extract: Women's Health Company Freya Biosciences Announces Key $ 10.4 Million Strategic Investment.
Document Source: https://www.prnewswire.com/news-releases/womens-health-company-freya-biosciences-announces-key-10-4-million-strategic-investment-302308946.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, noon / Source: PR Newswire
Activity Class: PartnershipActivity
/ Region: United States
Partnership:
- Alife Health
/ Industry: Fertility Technology, Health, And Wellness and 1 more
- US Fertility
/ Industry: Fertility Technology, Hospital Management Service
- Alife Health
/ Industry: Fertility Technology, Health, And Wellness and 1 more
- US Fertility
/ Industry: Fertility Technology, Hospital Management Service
Document Extract: With more than 200 physicians in fertility centers nationwide, US Fertility performs over 50,000 IVF retrieval cycles annually and has helped more than 225,000 individuals and couples on their journey to build their families through assisted reproductive technology. The pilot of Embryo Assist™ is expected to further enhance US Fertility's data capabilities and patient integration. " Alife is honored to partner with US Fertility to bring our cutting-edge AI solutions into their laboratories ," said Melissa Teran, CEO of Alife Health. " Through this pilot collaboration, we will equip embryologists with a powerful tool that streamlines operations and enhances clinical efficiency. Together, we are advancing IVF through innovation ."
Document Source: https://www.prnewswire.com/news-releases/alife-health-partners-with-us-fertility-to-pilot-embryology-laboratory-ai-tools-302307315.html
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 7:30 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
/ Region: Japan
Partnership:
- Cytokinetics
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 3 more
- Cytokinetics
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 3 more
- Bayer
/ Industry: Agricultural Technology, Biopharmaceutical And Biotech Industry and 14 more
- Bayer
/ Industry: Agricultural Technology, Biopharmaceutical And Biotech Industry and 14 more
Document Extract: Up to €490 Million in Commercial Milestone Payments, with. Tiered Royalties on Future Sales. SOUTH SAN FRANCISCO, Calif. and BERLIN, Nov. 19, 2024 (GLOBE NEWSWIRE) - Cytokinetics, Incorporated (Nasdaq: CYTK) and Bayer today announced they have entered into a collaboration and license agreement for the exclusive development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) , subject to certain reserved development rights of Cytokinetics. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. Cytokinetics will receive an upfront payment of €50 million and is eligible to receive up to an additional €90 million upon the achievement of milestones through commercial launch, including €20 million which are near-term.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983285/35409/en/Cytokinetics-and-Bayer-Announce-Exclusive-Licensing-Collaboration-for-Aficamten-in-Japan.html
(archive.org page /
archive.org listing)
Document Date: Nov. 21, 2024, 12:49 p.m. / Source: Hotel Management
Activity Class: CorporateFinanceActivity
/ Type: Acquisition
/ Region: Kingdom of Sweden
Buyer:
- Mews
/ Industry: Fertility Technology, Hospitality Technology Solutions and 1 more
Target:
Document Extract: Mews acquires RMS provider Atomize.
Document Source: https://www.hotelmanagement.net/tech/mews-acquires-rms-provider-atomize
(archive.org page /
archive.org listing)
Document Date: Nov. 21, 2024, 11 a.m. / Source: PR Newswire
Activity Class: CorporateFinanceActivity
/ Type: Acquisition
/ Region: Kingdom of Sweden
Buyer:
- Mews
/ Industry: Fertility Technology, Hospitality Technology Solutions and 1 more
Target:
- Atomize
/ Industry: Hospitality Technology Solutions
Document Extract: Mews Acquires Atomize Unlocking Huge Revenue Opportunities for Hoteliers.
Document Source: https://www.prnewswire.com/news-releases/mews-acquires-atomize-unlocking-huge-revenue-opportunities-for-hoteliers-302312031.html
(archive.org page /
archive.org listing)
Document Date: Nov. 22, 2024, 11:30 a.m. / Source: Business Wire
Activity Class: RoleActivity
/ Type: Starting
/ Region: Canada, United States
Role:
Person:
Organization:
- Merck
/ Industry: Animal Health Diagnostics, Biopharmaceutical And Biotech Industry and 22 more
- Merck
/ Industry: Animal Health Diagnostics, Biopharmaceutical And Biotech Industry and 21 more
Document Extract: Merck (NYSE: MRK) , known as MSD outside of the United States and Canada, today announced that Surendralal L. "Lal" Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE: EMR) , will join Merck's board of directors effective January 1, 2025.
Document Source: https://www.businesswire.com/news/home/20241122809362/en/Surendralal-Karsanbhai-Elected-to-Merck-Board-of-Directors
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? Yes
(Turn Off)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.